Ventricular tachycardia in coronary artery disease
Begoña Benito1, Mark E Josephson
1Sección de Arritmias, Servicio de Cardiología, Hospital del Mar, Barcelona, España.
Insights
Ventricular tachycardia (VT) remains a significant risk in coronary artery disease patients. This review covers diagnosis, electrophysiology, and ablation strategies for managing VT, alongside other therapies like drugs and ICDs.
Area of Science:
- Cardiology
- Electrophysiology
- Cardiac Surgery
Background:
- Ventricular arrhythmias significantly contribute to morbidity and mortality in patients with coronary artery disease (CAD).
- Ventricular fibrillation is a leading cause of death during acute ischemia, while sustained monomorphic ventricular tachycardia (VT) often arises from scar tissue in healed myocardial infarction, particularly with reduced left ventricular ejection fraction.
- Despite advances, VT risk in the CAD population remains a clinical challenge.
Purpose of the Study:
- To review the current understanding and management of ventricular tachycardia in patients with coronary artery disease.
- To outline diagnostic and therapeutic strategies for ventricular tachycardia associated with coronary artery disease.
Main Methods:
- Review of diagnostic tools including 12-lead electrocardiogram and invasive electrophysiologic study.
- Discussion of ventricular tachycardia ablation approaches based on inducibility, sustainability, and clinical tolerance.
- Overview of alternative therapies such as antiarrhythmic drugs, surgical ablation, and implantable cardioverter-defibrillator (ICD) indications.
Main Results:
- Electrocardiogram aids in diagnosis and localization of VT circuits.
- Electrophysiologic studies are crucial for determining arrhythmia mechanisms and guiding ablation.
- VT ablation strategies are tailored to individual patient factors.
Conclusions:
- Ventricular tachycardia in CAD is a complex issue requiring a multi-faceted management approach.
- Integrated strategies involving diagnostic studies, ablation, antiarrhythmic drugs, and device therapy are essential for optimal patient outcomes.
Abstract:
Ventricular arrhythmias are important contributors to morbidity and mortality in patients with coronary artery disease. Ventricular fibrillation accounts for the majority of deaths occurring in the acute phase of ischemia, whereas sustained, monomorphic ventricular tachycardia due to reentry generated in the scar tissue develops most often in the setting of healed myocardial infarction, especially in patients with lower left ventricular ejection fraction. Despite determinant advances in population education and myocardial infarction management, the ventricular tachycardia risk in the overall population with coronary artery disease continues to be a major problem in clinical practice. The initial evaluation of a patient presenting with ventricular tachycardia requires a 12-lead electrocardiogram, which can be helpful to confirm the diagnosis, suggest the presence of potential underlying heart disease, and identify the location of the ventricular tachycardia circuit. An invasive electrophysiologic study is usually crucial to determine the mechanism of the arrhythmia once induced and to provide guidance for ablation. The approach for ventricular tachycardia ablation depends on several factors, including inducibility, sustainability, and clinical tolerance of ventricular tachycardia. The paper also reviews other therapeutic options for patients with ventricular tachycardia associated with coronary artery disease, including antiarrhythmic drug therapy, surgical ablation, and current implantable cardioverter-defibrillator indications.
Related Concept Videos
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Dysrhythmias III: Characteristics of Dysrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Coronary Artery Disease III: Clinical Manifestations
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Coronary Artery Disease II: Pathophysiology


